In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures

Lucy C. Crossman, Motomi (Tomi) Mori, Yi Ching Hsieh, Thoralf Lange, Peter Paschka, Christina (Chris) Harrington, Knut Krohn, Dietger W. Niederwieser, Rüdiger Hehlmann, Andreas Hochhaus, Brian Druker, Michael W N Deininger

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background and Objectives. Imatinib induces complete cytogenetic responses (CCR) in the majority of patients with chronic myeloid leukemia (CML) in chronic phase (CP). However, a subgroup of patients is refractory at the cytogenetic level. Clinically, it would be advantageous to identify such patients a priori, since they may benefit from more aggressive therapy. Design and Methods. To elucidate mechanisms underlying cytogenetic refractoriness, we used Affymetrix oligonucleotide arrays to determine the transcriptional signature associated with cytogenetic refractoriness in unselected white blood or bone marrow cells from 29 patients with CML in first CP prior to treatment with imatinib. Patients with CCR within 9 months were defined as responders (n = 16) and patients lacking a major cytogenetic response (>35% Philadelphia-positive metaphases) after 1 year were defined as non-responders (n = 13). Results. Differences in gene expression between responders and non-responders were subtle. Stringent statistical analysis with multiple comparison adjustments revealed very few differentially expressed genes. Differentially expressed genes could not be confirmed in an independent test set. Interpretation and Conclusions. We conclude that transcriptional profiling of unselected white cells is of limited value for identifying genes consistently associated with cytogenetic refractoriness to imatinib.

Original languageEnglish (US)
Pages (from-to)459-464
Number of pages6
JournalHaematologica
Volume90
Issue number4
StatePublished - Apr 2005

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Transcriptome
Cytogenetics
Genes
Leukemia, Myeloid, Chronic Phase
Metaphase
Imatinib Mesylate
Oligonucleotide Array Sequence Analysis
Bone Marrow Cells
Gene Expression
Therapeutics

Keywords

  • CML
  • Cytogenetic refractoriness
  • Gene expression profiling
  • Imatinib

ASJC Scopus subject areas

  • Hematology

Cite this

In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. / Crossman, Lucy C.; Mori, Motomi (Tomi); Hsieh, Yi Ching; Lange, Thoralf; Paschka, Peter; Harrington, Christina (Chris); Krohn, Knut; Niederwieser, Dietger W.; Hehlmann, Rüdiger; Hochhaus, Andreas; Druker, Brian; Deininger, Michael W N.

In: Haematologica, Vol. 90, No. 4, 04.2005, p. 459-464.

Research output: Contribution to journalArticle

Crossman, LC, Mori, MT, Hsieh, YC, Lange, T, Paschka, P, Harrington, CC, Krohn, K, Niederwieser, DW, Hehlmann, R, Hochhaus, A, Druker, B & Deininger, MWN 2005, 'In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures', Haematologica, vol. 90, no. 4, pp. 459-464.
Crossman, Lucy C. ; Mori, Motomi (Tomi) ; Hsieh, Yi Ching ; Lange, Thoralf ; Paschka, Peter ; Harrington, Christina (Chris) ; Krohn, Knut ; Niederwieser, Dietger W. ; Hehlmann, Rüdiger ; Hochhaus, Andreas ; Druker, Brian ; Deininger, Michael W N. / In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. In: Haematologica. 2005 ; Vol. 90, No. 4. pp. 459-464.
@article{d7768b7ef05244ba967a234ff7d05f9e,
title = "In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures",
abstract = "Background and Objectives. Imatinib induces complete cytogenetic responses (CCR) in the majority of patients with chronic myeloid leukemia (CML) in chronic phase (CP). However, a subgroup of patients is refractory at the cytogenetic level. Clinically, it would be advantageous to identify such patients a priori, since they may benefit from more aggressive therapy. Design and Methods. To elucidate mechanisms underlying cytogenetic refractoriness, we used Affymetrix oligonucleotide arrays to determine the transcriptional signature associated with cytogenetic refractoriness in unselected white blood or bone marrow cells from 29 patients with CML in first CP prior to treatment with imatinib. Patients with CCR within 9 months were defined as responders (n = 16) and patients lacking a major cytogenetic response (>35{\%} Philadelphia-positive metaphases) after 1 year were defined as non-responders (n = 13). Results. Differences in gene expression between responders and non-responders were subtle. Stringent statistical analysis with multiple comparison adjustments revealed very few differentially expressed genes. Differentially expressed genes could not be confirmed in an independent test set. Interpretation and Conclusions. We conclude that transcriptional profiling of unselected white cells is of limited value for identifying genes consistently associated with cytogenetic refractoriness to imatinib.",
keywords = "CML, Cytogenetic refractoriness, Gene expression profiling, Imatinib",
author = "Crossman, {Lucy C.} and Mori, {Motomi (Tomi)} and Hsieh, {Yi Ching} and Thoralf Lange and Peter Paschka and Harrington, {Christina (Chris)} and Knut Krohn and Niederwieser, {Dietger W.} and R{\"u}diger Hehlmann and Andreas Hochhaus and Brian Druker and Deininger, {Michael W N}",
year = "2005",
month = "4",
language = "English (US)",
volume = "90",
pages = "459--464",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "4",

}

TY - JOUR

T1 - In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures

AU - Crossman, Lucy C.

AU - Mori, Motomi (Tomi)

AU - Hsieh, Yi Ching

AU - Lange, Thoralf

AU - Paschka, Peter

AU - Harrington, Christina (Chris)

AU - Krohn, Knut

AU - Niederwieser, Dietger W.

AU - Hehlmann, Rüdiger

AU - Hochhaus, Andreas

AU - Druker, Brian

AU - Deininger, Michael W N

PY - 2005/4

Y1 - 2005/4

N2 - Background and Objectives. Imatinib induces complete cytogenetic responses (CCR) in the majority of patients with chronic myeloid leukemia (CML) in chronic phase (CP). However, a subgroup of patients is refractory at the cytogenetic level. Clinically, it would be advantageous to identify such patients a priori, since they may benefit from more aggressive therapy. Design and Methods. To elucidate mechanisms underlying cytogenetic refractoriness, we used Affymetrix oligonucleotide arrays to determine the transcriptional signature associated with cytogenetic refractoriness in unselected white blood or bone marrow cells from 29 patients with CML in first CP prior to treatment with imatinib. Patients with CCR within 9 months were defined as responders (n = 16) and patients lacking a major cytogenetic response (>35% Philadelphia-positive metaphases) after 1 year were defined as non-responders (n = 13). Results. Differences in gene expression between responders and non-responders were subtle. Stringent statistical analysis with multiple comparison adjustments revealed very few differentially expressed genes. Differentially expressed genes could not be confirmed in an independent test set. Interpretation and Conclusions. We conclude that transcriptional profiling of unselected white cells is of limited value for identifying genes consistently associated with cytogenetic refractoriness to imatinib.

AB - Background and Objectives. Imatinib induces complete cytogenetic responses (CCR) in the majority of patients with chronic myeloid leukemia (CML) in chronic phase (CP). However, a subgroup of patients is refractory at the cytogenetic level. Clinically, it would be advantageous to identify such patients a priori, since they may benefit from more aggressive therapy. Design and Methods. To elucidate mechanisms underlying cytogenetic refractoriness, we used Affymetrix oligonucleotide arrays to determine the transcriptional signature associated with cytogenetic refractoriness in unselected white blood or bone marrow cells from 29 patients with CML in first CP prior to treatment with imatinib. Patients with CCR within 9 months were defined as responders (n = 16) and patients lacking a major cytogenetic response (>35% Philadelphia-positive metaphases) after 1 year were defined as non-responders (n = 13). Results. Differences in gene expression between responders and non-responders were subtle. Stringent statistical analysis with multiple comparison adjustments revealed very few differentially expressed genes. Differentially expressed genes could not be confirmed in an independent test set. Interpretation and Conclusions. We conclude that transcriptional profiling of unselected white cells is of limited value for identifying genes consistently associated with cytogenetic refractoriness to imatinib.

KW - CML

KW - Cytogenetic refractoriness

KW - Gene expression profiling

KW - Imatinib

UR - http://www.scopus.com/inward/record.url?scp=20944438747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20944438747&partnerID=8YFLogxK

M3 - Article

C2 - 15820940

AN - SCOPUS:20944438747

VL - 90

SP - 459

EP - 464

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 4

ER -